



ISSUE DATE September 1, 2021	EFFECTIVE DATE August 12, 2021	NUMBER 01-21-12, 05-21-06, 08-21-13, 09-21-10, 11-21-02, 24-21-09, 26-21-04, 30-21-07 31-21-13, 33-21-10
SUBJECT Administration of a Third Dose of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna, Inc.		BY  Sally A. Kozak, Deputy Secretary Office of Medical Assistance Programs

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx>.

PURPOSE:

The purpose of this bulletin is to inform Medical Assistance (MA) providers that the Department of Human Services (Department) added Current Procedural Terminology (CPT) codes 0003A and 0013A to the MA Program Fee Schedule for the administration of a third dose of the novel coronavirus (SARS-CoV-2) vaccines manufactured by Pfizer, Inc. and Moderna, Inc.

SCOPE:

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, outpatient hospital-based clinics, independent medical/surgical clinics, home health agencies, ambulance providers, renal dialysis centers, psychiatric outpatient clinics, drug and alcohol outpatient clinics, partial psychiatric hospitals, and licensed pharmacies enrolled in the MA Program who may administer SARS-CoV-2 vaccines to MA beneficiaries in the Fee-for-Service (FFS) or managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate managed care organization with any billing questions.

BACKGROUND/DISCUSSION:

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx>.

On August 12, 2021, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) for both the Pfizer, Inc. and Moderna, Inc. SARS-CoV-2 vaccines to allow for a third dose of the vaccine by these manufacturers.

On August 19, 2021, the Centers for Medicare & Medicaid Services (CMS) announced the implementation of procedure code 0003A for the Pfizer, Inc. vaccine and 0013A for the Moderna, Inc. vaccine, effective August 12, 2021. The codes are distinct to the third dose of the SARS-CoV-2 vaccines below. This level of specificity offers the ability to track each vaccine, even when the vaccine product is not reported, such as when the vaccine is available at no cost.

In response, the Department added CPT codes 0003A and 0013A to the MA Program Fee Schedule, which may be used for dates of service on and after August 12, 2021. These codes are to be used by providers in both the FFS and managed care delivery systems to enable the Department to identify the specific SARS-CoV-2 vaccines that have been administered.

PROCEDURE:

Effective August 12, 2021, MA providers in both the FFS and managed care delivery systems are to bill for the administration of a third dose of the SARS-CoV-2 vaccines manufactured by Pfizer, Inc. and Moderna, Inc. to MA beneficiaries using the CPT codes below.

Vaccine Manufacturer	Code	Code Description
Pfizer, Inc.	0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose
Moderna, Inc.	0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose

Attached is the “Addition to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of a Third Dose of SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc. and Moderna, Inc., Effective August 12, 2021”. The attachment identifies the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, and MA fee for the procedure code for providers submitting MA FFS claims.

MA providers who administer a third dose of a SARS-CoV-2 vaccine to a MA beneficiary who is homebound should refer to MA Bulletin 01-21-04, “SARS-CoV-2 Vaccine Administration for Beneficiaries who are Homebound” for billing instructions. The bulletin may

be accessed at the link below:

<https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2021072901.pdf>.

Providers may access the online version of the MA Program Fee Schedule on the Department's website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx>.

MA providers may also bill the MA Program for the vaccine for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code and the units dispensed for the vaccine. Providers may access the online version of the MA Drug Fee Schedule on the Department's website at: <https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx>.

Providers may not bill the MA Program for a vaccine they receive at no cost, including SARS-CoV-2 vaccines purchased by the federal government.

For information on how licensed pharmacies enrolled in the MA Program who provide services to MA beneficiaries should bill for the administration of SARS-CoV-2 vaccines by a pharmacist, please refer to MA Bulletin 01-20-60, "SARS-CoV-2 Vaccine Administration by Pharmacists", issued December 30, 2020, at the link below:

<https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2020123001.pdf>.

Additional information and guidance pertaining to the SARS-CoV-2 vaccines can be found at the following links:

- American Medical Association
<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>.
- Centers for Disease Control and Prevention
<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html>.
- Centers for Medicare & Medicaid Services
<https://www.medicare.gov/resources-for-states/disaster-response-toolkit/coronavirus-disease-2019-covid-19/index.html>.
- Pennsylvania Department of Health
<https://www.health.pa.gov/Pages/default.aspx>.

ATTACHMENT:

Addition to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of a Third Dose of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna, Inc., Effective August 12, 2021

**Addition to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of a Third Dose of SARS-CoV-2 Vaccines
Manufactured by Pfizer, Inc. and Moderna, Inc., Effective August 12, 2021**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	01	183	12, 22			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	05	050, 051	12, 99			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	08	082	12, 49			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	08	110	11, 49, 99			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	08	184	57, 99			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	11	110, 127	99			\$40.00	No	once per day

0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	11	113, 114	52			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	24	All	11, 31, 32, 99			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	24	240, 247	12			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	26	260, 261	12, 99			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	30	300	12, 65			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	33	335	11, 12, 99			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	01	183	12, 22			\$40.00	No	once per day

0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	05	050, 051	12, 99			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	08	082	12, 49			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	08	110	11, 49, 99			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	08	184	57, 99			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	11	110, 127	99			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	11	113, 114	52			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	24	All	11, 31, 32, 99			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	24	240, 247	12			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	26	260, 261	12, 99			\$40.00	No	once per day

0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	30	300	12, 65			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	33	335	11, 12, 99			\$40.00	No	once per day